The subclass of compounds which have the nucleus 1,4-naphthoquinone is the most various of the class of quinones, which have a big quantity of substances and a number of which have helpful purposes starting from medicinal chemistry to software in supplies with particular properties. The introduction of one or two substituents with the sulfur heteroatom in the naphthoquinone nucleus generates merchandise containing alkyl and aryl teams that amplify sure organic properties in opposition to micro organism, viruses and fungi. The inexperienced, purple, and brown algae have been proven to have helpful therapeutic properties in the prevention and therapy of neurodegenerative illnesses: Parkinson, Alzheimer’s, and Multiple Sclerosis, and different persistent illnesses.
There are a number of strategies of getting ready these compounds, primarily from low molecular weight naphthoquinones with two electrophilic websites succesful of reacting with sulfides producing variety and new lessons of compounds, together with new sulfur heterocycles and sulfur heterocycles fused with naphthoquinones. These compounds have been proven to be bioactive in opposition to a number of organic targets. This overview will describe the strategies of their synthesis and, when relevant, their organic actions.
Edible marine algae are wealthy in bioactive compounds and are, subsequently, a supply of bioavailable proteins, lengthy chain polysaccharides that behave as low-calorie soluble fibers, metabolically needed minerals, nutritional vitamins, polyunsaturated fatty acids, and antioxidants. Marine algae have been used primarily as gelling brokers and thickeners (phycocolloids) in meals and pharmaceutical industries in the final century, however latest analysis has revealed their potential as a supply of helpful compounds for the pharmaceutical, medical, and beauty industries. In this overview are listed and described the essential parts of an appropriate eating regimen for sufferers with these illnesses. In addition, compounds derived from macroalgae and their neurophysiological actions are described.
Antiviral and immunomodulatory exercise of curcumin: A case for prophylactic remedy for COVID-19
Coronavirus disease-19 (COVID-19), a devastating respiratory sickness brought on by SARS-associated coronavirus-2 (SARS-CoV-2), has already affected over 64 million folks and triggered 1.48 million deaths, simply 12 months from the first prognosis. COVID-19 sufferers develop critical issues, together with extreme pneumonia, acute respiratory misery syndrome (ARDS), and or multiorgan failure on account of exaggerated host immune response following an infection. Currently, medication that have been efficient in opposition to SARS-CoV are being repurposed for SARS-CoV-2. During this public well being emergency, meals nutraceuticals may very well be promising prophylactic therapeutics for COVID-19.
Curcumin, a bioactive compound in turmeric, exerts various pharmacological actions and is extensively utilized in meals and conventional medicines. This overview presents a number of strains of proof, which counsel curcumin as a promising prophylactic, therapeutic candidate for COVID-19. First, curcumin exerts antiviral exercise in opposition to many sorts of enveloped viruses, together with SARS-CoV-2, by a number of mechanisms: direct interplay with viral membrane proteins; disruption of the viral envelope; inhibition of viral proteases; induce host antiviral responses. Second, curcumin protects from deadly pneumonia and ARDS by way of focusing on NF-κB, inflammasome, IL-6 trans sign, and HMGB1 pathways.
Breast most cancers is the most frequent feminine most cancers and one of the main causes of most cancers demise in girls. There are many chemotherapy brokers accessible for the therapy of breast most cancers, however the present therapeutic choices haven’t fulfilled the desired outcomes particularly for the drug-resistant breast most cancers remedy. Thus, there may be an pressing must develop novel anti-breast most cancers brokers. Coumarin is ubiquitous in pure and artificial bioactive compounds, and coumarin derivatives are readily interacting with a range of enzymes and receptors in breast most cancers cells.
Moreover, the coumarin-based Irosustat as the first-generation steroid sulfatase inhibitor in breast most cancers is below scientific evaluations, revealing the potential of coumarin derivatives as novel anti-breast most cancers brokers. This overview goals to explain the latest growth of pure and artificial coumarin derivatives with anti-breast most cancers potential, protecting the articles printed from 2015 to 2020. Third, curcumin is protected and well-tolerated in each wholesome and diseased human topics. In conclusion, collected proof signifies that curcumin could also be a possible prophylactic therapeutic for COVID-19 in the clinic and public well being settings.
Phytochemical screening, in vitro antioxidant and enzyme inhibitory proprieties and acute toxicity of extracts from the aerial elements of Ephedra nebrodensis, supply of bioactive compounds
The goal of this examine was to judge the in vitro antioxidant and the enzyme inhibitory properties and to establish the bioactive compounds current in the extracts of Ephedra nebrodensis rising in Algeria. Total phenolic and flavonoids content material in these extracts have been quantified by Folin-Ciocalteu and aluminum chloride strategies. The antioxidant capability was assessed utilizing DPPH, ABTS, β-carotene/linoleic acid, CUPRAC and FRAP assays and in vitro cholinesterase exercise in opposition to acetylcholinesterase and butyrylcholinesterase have been evaluated. The chemical constituents of the extracts have been analyzed by high-performance liquid chromatography coupled to mass spectrometric detection and gasoline chromatography coupled to mass spectrometric detection. For the acute toxicity examine, extracts have been administered to mice at single dose of 2 g/kg and 5 g/kg by gavage.
 LILRB4 / CD85k / ILT3 Recombinant Protein |
|
11-320 |
ProSci |
0.1 mg |
EUR 595.25 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
LILRB4 / CD85k / ILT3 Recombinant Protein |
|
11-484 |
ProSci |
0.1 mg |
EUR 595.25 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
LILRB4 / CD85k / ILT3 Recombinant Protein |
|
11-491 |
ProSci |
0.1 mg |
EUR 658.25 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
 Recombinant human LILRB4/CD85k/ILT3 Protein |
|
RP01155 |
Abclonal |
10 μg |
EUR 230 |
Recombinant human LILRB4/CD85k/ILT3 Protein |
|
RP01185 |
Abclonal |
10 μg |
EUR 193 |
 Human CellExp? LILRB4 / CD85k / ILT3, Cynomolgus Recombinant |
|
P1187-10 |
Biovision |
|
EUR 164 |
Human CellExp? LILRB4 / CD85k / ILT3, Cynomolgus Recombinant |
|
P1187-50 |
Biovision |
|
EUR 544 |
 Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant |
|
P1188-10 |
Biovision |
|
EUR 164 |
Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant |
|
P1188-50 |
Biovision |
|
EUR 588 |
Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant |
|
P1200-10 |
Biovision |
|
EUR 185 |
Human CellExp? LILRB4 / CD85k / ILT3, Mouse Recombinant |
|
P1200-50 |
Biovision |
|
EUR 729 |
) Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His) |
|
CS97-10ug |
Novoprotein |
10ug |
EUR 156 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His) |
|
CS97-1mg |
Novoprotein |
1mg |
EUR 1877 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His) |
|
CS97-500ug |
Novoprotein |
500ug |
EUR 1328 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
Recombinant Mouse LILRB4/CD85k/ILT3 (C-6His) |
|
CS97-50ug |
Novoprotein |
50ug |
EUR 369 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4. |
 ELISA Kit) Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit |
|
RD-LILRB4-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 500 |
Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit |
|
RD-LILRB4-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 692 |
Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit |
|
DLR-LILRB4-Hu-48T |
DL Develop |
48T |
EUR 498 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) in samples from tissue homogenates, cell lysates or other biological fluids. |
Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit |
|
DLR-LILRB4-Hu-96T |
DL Develop |
96T |
EUR 647 |
|
|
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) in samples from tissue homogenates, cell lysates or other biological fluids. |
Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit |
|
RDR-LILRB4-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 522 |
Human Leukocyte Immunoglobulin Like Receptor Subfamily B, Member 4 (LILRB4) ELISA Kit |
|
RDR-LILRB4-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 724 |
) LILRB4 Recombinant Protein (Human) |
|
RP017800 |
ABM |
100 ug |
Ask for price |
 LILRB4 Recombinant Protein |
|
96-518 |
ProSci |
0.05 mg |
EUR 626.75 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
LILRB4 Recombinant Protein |
|
96-808 |
ProSci |
0.1 mg |
EUR 710.75 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
LILRB4 Recombinant Protein |
|
96-809 |
ProSci |
0.1 mg |
EUR 710.75 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
LILRB4 Recombinant Protein |
|
97-012 |
ProSci |
0.1 mg |
EUR 710.75 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
LILRB4 Recombinant Protein |
|
97-013 |
ProSci |
0.1 mg |
EUR 710.75 |
|
Description: Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) is also known as CD85 antigen-like family member K (CD85K), Immunoglobulin-like transcript 3 (ILT-3), Leukocyte immunoglobulin-like receptor 5 (LIR-5), Monocyte inhibitory receptor HM18, which belongs to the leukocyte immunoglobulin-like receptor (LIR) family. LILRB4 / CD85K contains 2 Ig-like C2-type (immunoglobulin-like) domains. CD85K is detected in monocytes, macrophages, dendritic cells, lung, natural killer cells and B-cells. LILRB4 / CD85K is receptor for class I MHC antigens. CD85K recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles, involved in the down-regulation of the immune response and the development of tolerance. LILRB4 interferes with TNFRSF5-signaling and NF-kappa-B up-regulation and inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
 DiscoveryProbe? Bioactive Compound Library |
|
L1022-.1 |
ApexBio |
100 uL/well(10 mM solution) |
EUR 23389 |
DiscoveryProbe? Bioactive Compound Library |
|
L1022-.25 |
ApexBio |
250 uL/well(10 mM solution) |
EUR 42042 |
DiscoveryProbe? Bioactive Compound Library |
|
L1022-5 |
ApexBio |
5 mg/well |
EUR 54686 |
 Cyclophilin-F Rat Recombinant Protein Bioactive |
|
PROTP29117-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
|
Description: Cyclophilin F Rat Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 200 amino acids (30-206 a.a) and having a molecular mass of 21.2Da. Cyclophilin F is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
 LILRB4 Antibody |
|
CSB-PA297929- |
Cusabio |
|
EUR 335 |
|
|
|
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IF;IF:1:100-1:500 |
LILRB4 Antibody |
|
CSB-PA297929-100ul |
Cusabio |
100ul |
EUR 316 |
|
|
|
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IF;IF:1:100-1:500 |
LILRB4 Antibody |
|
1-CSB-PA006757 |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: IF, ELISA;IF:1/200-1/1000.ELISA:1/20000 |
LILRB4 Antibody |
|
1-CSB-PA850914ESR1HU |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:1000-1:5000 |
LILRB4 Antibody |
|
1-CSB-PA850914ESR2HU |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against LILRB4. Recognizes LILRB4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200 |
LILRB4 Antibody |
|
34759-100ul |
SAB |
100ul |
EUR 252 |
LILRB4 Antibody |
|
34759-50ul |
SAB |
50ul |
EUR 187 |
 LILRB4 siRNA |
|
20-abx922563 |
Abbexa |
|
|
|
|
LILRB4 siRNA |
|
20-abx922564 |
Abbexa |
|
|
|
|
 anti-LILRB4 |
|
YF-PA25711 |
Abfrontier |
50 ul |
EUR 334 |
|
Description: Mouse polyclonal to LILRB4 |
 LILRB4 antibody |
|
70R-35844 |
Fitzgerald |
100 ug |
EUR 327 |
|
Description: Rabbit polyclonal LILRB4 antibody |
) LILRB4 Recombinant Protein (Rat) |
|
RP208181 |
ABM |
100 ug |
Ask for price |
) LILRB4 Recombinant Protein (Mouse) |
|
RP147467 |
ABM |
100 ug |
Ask for price |
 Human LILRB4 shRNA Plasmid |
|
20-abx957516 |
Abbexa |
|
|
|
|
 DCXR Human, Dicarbonyl/L-Xylulose Reductase Human Recombinant Protein, Bioactive |
|
PROTQ7Z4W1-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
|
Description: DCXR Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 264 amino acids (1-244 a.a.) and having a molecular mass of 28 kDa. The DCXR is fused to a 20 amino acids His-Tag at N-terminus and purified by proprietary chromatographic techniques. |
 LILRB4 cloning plasmid |
|
CSB-CL850914HU-10ug |
Cusabio |
10ug |
EUR 233 |
|
|
|
Description: A cloning plasmid for the LILRB4 gene. |
 Anti-LILRB4 antibody |
|
STJ29153 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. |
 LILRB4 Rabbit pAb |
|
A7073-100ul |
Abclonal |
100 ul |
EUR 308 |
LILRB4 Rabbit pAb |
|
A7073-200ul |
Abclonal |
200 ul |
EUR 459 |
LILRB4 Rabbit pAb |
|
A7073-20ul |
Abclonal |
20 ul |
EUR 183 |
LILRB4 Rabbit pAb |
|
A7073-50ul |
Abclonal |
50 ul |
EUR 223 |
 LILRB4 Conjugated Antibody |
|
C34759 |
SAB |
100ul |
EUR 397 |
 (OKEH01767)) LILRB4 ELISA Kit (Human) (OKEH01767) |
|
OKEH01767 |
Aviva Systems Biology |
96 Wells |
EUR 662 |
|
Description: Description of target: This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.082 ng/mL |
 (OKCD07380)) LILRB4 ELISA Kit (Human) (OKCD07380) |
|
OKCD07380 |
Aviva Systems Biology |
96 Wells |
EUR 936 |
|
Description: Description of target: Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab);Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 0.057ng/mL |
 (pORF)) LILRB4 ORF Vector (Human) (pORF) |
|
ORF005934 |
ABM |
1.0 ug DNA |
EUR 95 |
 Human CellExp? LILRB4, Cynomolgus Recombinant |
|
P1199-10 |
Biovision |
|
EUR 185 |
Human CellExp? LILRB4, Cynomolgus Recombinant |
|
P1199-50 |
Biovision |
|
EUR 729 |
 (pPB-C-His)) LILRB4 Protein Vector (Human) (pPB-C-His) |
|
PV023733 |
ABM |
500 ng |
EUR 329 |
 (pPB-N-His)) LILRB4 Protein Vector (Human) (pPB-N-His) |
|
PV023734 |
ABM |
500 ng |
EUR 329 |
 (pPM-C-HA)) LILRB4 Protein Vector (Human) (pPM-C-HA) |
|
PV023735 |
ABM |
500 ng |
EUR 329 |
 (pPM-C-His)) LILRB4 Protein Vector (Human) (pPM-C-His) |
|
PV023736 |
ABM |
500 ng |
EUR 329 |
 (C-Fc Tag)) LILRB4 Recombinant Protein (Human) (C-Fc Tag) |
|
RP238855 |
ABM |
1mg |
Ask for price |
LILRB4 Recombinant Protein (Human) (C-Fc Tag) |
|
RP238856 |
ABM |
50ug |
Ask for price |
 ENTPD3 Human, Ectonucleoside Triphosphate Diphosphohydrolase 3 Human Recombinant Protein, sf9 Bioactive |
|
PROTO75355-2 |
BosterBio |
Regular: 4ug |
EUR 317 |
|
Description: ENTPD3 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 451 amino acids (44-485a.a.) and having a molecular mass of 50.7kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa).;ENTPD3 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques. |
 Mouse LILRB4 shRNA Plasmid |
|
20-abx970615 |
Abbexa |
|
|
|
|
 Anti-LILRB4/Gp49 Antibody |
|
A04924 |
BosterBio |
100ul |
EUR 397 |
|
Description: Rabbit Polyclonal LILRB4/Gp49 Antibody. Validated in IF and tested in Human. |
 [His]) Human LILRB4 Protein (Gln 22-Glu 259) [His] |
|
VAng-1892Lsx-100g |
Creative Biolabs |
100 µg |
EUR 1013 |
|
Description: Human LILRB4 protein, His tag, expressed in human 293 cells. (Uniprot ID: AAH26309.1) |
Human LILRB4 Protein (Gln 22-Glu 259) [His] |
|
VAng-1892Lsx-1mg |
Creative Biolabs |
1 mg |
EUR 6402 |
|
Description: Human LILRB4 protein, His tag, expressed in human 293 cells. (Uniprot ID: AAH26309.1) |
) LILRB4 sgRNA CRISPR Lentivector set (Human) |
|
K1215601 |
ABM |
3 x 1.0 ug |
EUR 339 |
 IMPAD1 Inositol Monophosphatase Domain Containing 1 Mouse Recombinant Protein Bioactive |
|
PROTQ80V26-1 |
BosterBio |
Regular: 10ug |
EUR 317 |
|
Description: IMPAD1 Mouse Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 332 amino acids (34-356a.a.) and having a molecular mass of 36.2kDa. (Molecular size on SDS-PAGE will appear at approximately 28-40kDa). IMPAD1 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques. |
 (pPB-C-His)) LILRB4 Protein Vector (Rat) (pPB-C-His) |
|
PV277578 |
ABM |
500 ng |
EUR 603 |
 (pPB-N-His)) LILRB4 Protein Vector (Rat) (pPB-N-His) |
|
PV277579 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-HA)) LILRB4 Protein Vector (Rat) (pPM-C-HA) |
|
PV277580 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-His)) LILRB4 Protein Vector (Rat) (pPM-C-His) |
|
PV277581 |
ABM |
500 ng |
EUR 603 |
 (pPB-C-His)) LILRB4 Protein Vector (Mouse) (pPB-C-His) |
|
PV196626 |
ABM |
500 ng |
EUR 603 |
 (pPB-N-His)) LILRB4 Protein Vector (Mouse) (pPB-N-His) |
|
PV196627 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-HA)) LILRB4 Protein Vector (Mouse) (pPM-C-HA) |
|
PV196628 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-His)) LILRB4 Protein Vector (Mouse) (pPM-C-His) |
|
PV196629 |
ABM |
500 ng |
EUR 603 |
 (OKEH05081)) LILRB4 ELISA Kit (Mouse) (OKEH05081) |
|
OKEH05081 |
Aviva Systems Biology |
96 Wells |
EUR 662 |
|
Description: Description of target: Receptor for class I MHC antigens. Involved in the down-regulation of the immune response and the development of tolerance. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.177 ng/mL |
 (pORF)) Lilrb4 ORF Vector (Mouse) (pORF) |
|
ORF049157 |
ABM |
1.0 ug DNA |
EUR 95 |
 (pORF)) Lilrb4 ORF Vector (Rat) (pORF) |
|
ORF069395 |
ABM |
1.0 ug DNA |
EUR 506 |
 (Target 1)) LILRB4 sgRNA CRISPR Lentivector (Human) (Target 1) |
|
K1215602 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) LILRB4 sgRNA CRISPR Lentivector (Human) (Target 2) |
|
K1215603 |
ABM |
1.0 ug DNA |
EUR 154 |
Plant extracts have been wealthy in phenolic compounds. Ethyl acetate extract introduced the highest phenolic (238.44 ± 1.50 µg GAE /mg of extract) and flavonoid (21.12 ± 0.00 µg QE /mg of extract) contents. Likewise, ethyl acetate extract confirmed potent radical scavenging and decreasing properties. Ethanol: acetone extract confirmed inhibitory exercise in opposition to acetylcholinesterase, and was a potent inhibitor of butyrylcholinesterase. In all extracts, flavonoids have been the most ample compounds. The phytochemical investigation confirmed the presence of alkaloids (ephedrine and pseudo-ephedrine). In the acute toxicity, the LD50 was superior to five g/kg physique weight. There are usually not alterations in the histology of the liver and kidneys.
